Xilio Therapeutics (NASDAQ:XLO) Raised to Hold at Zacks Research

Xilio Therapeutics (NASDAQ:XLO) was upgraded by analysts at Zacks Research to a “hold” rating in a report issued on Thursday, Zacks reports.

Several other analysts have also recently commented on XLO. Weiss Ratings cut shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Raymond James Financial assumed coverage on shares of Xilio Therapeutics in a research note on Wednesday. They set an “outperform” rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $16.00.

Xilio Therapeutics Price Performance

Xilio Therapeutics stock opened at $7.57 on Thursday. Xilio Therapeutics has a 12 month low of $6.47 and a 12 month high of $12.58. The business has a 50 day simple moving average of $8.96 and a 200-day simple moving average of $8.73. The stock has a market capitalization of $49.81 million, a PE ratio of -4.61 and a beta of -0.15.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.26. The firm had revenue of $18.69 million for the quarter, compared to analyst estimates of $12.72 million. Xilio Therapeutics had a negative net margin of 34.06% and a negative return on equity of 71.99%. As a group, equities research analysts anticipate that Xilio Therapeutics will post -3.17 EPS for the current year.

Institutional Trading of Xilio Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Xilio Therapeutics in the second quarter valued at about $84,000. State Street Corp acquired a new stake in shares of Xilio Therapeutics during the 2nd quarter valued at approximately $128,000. Finally, Stonepine Capital Management LLC boosted its stake in shares of Xilio Therapeutics by 252.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 225,994 shares of the company’s stock worth $2,165,023 after acquiring an additional 161,832 shares in the last quarter. Institutional investors and hedge funds own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics, Inc is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep therapeutic agents inactive in healthy tissue and activate them within the tumor microenvironment, with the goal of improving treatment effectiveness while reducing systemic side effects.

Xilio’s development programs have included tumor-activated cytokines and other immune-modulating therapies, including XTX202, an investigational tumor-activated interleukin-2 program, and XTX301, an investigational tumor-activated interleukin-12 program.